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PharmacovigilanceAbstract Objective: Purpose of this study was to monitor adverse drug reactions reported from
various departments of a tertiary care hospital in Northeast India. Reported adverse drug reactions
were analysed for causality and severity assessment.
Methods: This cross sectional study was conducted in a tertiary care hospital at Guwahati, North-
east India, for 7 months. Patients of all age and either sex were included. Adverse drug reactions
were reported by the physicians of this hospital and their causality and severity assessments were
performed as per Naranjo’s and Hartwig’s assessment criteria respectively. Descriptive statistics
were used for data analysis.
Results: Total 255 adverse drug reactions were reported from various departments of this tertiary
care hospital. Most of the adverse drug reactions were observed in the age group of 21–30 year.
Acne (46) was commonly reported reaction. Topical steroids, betamethasone sodium phosphate
and clobetasol were reported to induce maximum number of reactions (59). Skin (227, 66.9%)
was commonly affected organ system. Most of the adverse drug reactions were possible (240,
94.1%) and mild (222, 87%) in nature.
Conclusions: The topical steroid (betamethasone sodium phosphate) was reported to induce
adverse drug reactions in majority of the patients. The commonly reported reaction was acne.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drugs prescribed for disease are often themselves the cause of
serious amount of adverse reactions ranging frommere inconve-
nience to permanent disability and death. According to DJP
Barker, ‘‘There are three actions of a drug: The one you want,.doi.org/
2 R.J. Lihite et al.the one you don’t want, and the one you don’t know about”.1
Since drugs are intended to relieve suffering, patients ﬁnd it par-
ticularly offensive that they can also cause disease. It has been
reported that ADRs account for 5% of all hospital admissions
and occur in 10–20% of hospitalized patients.2 An overall inci-
dence of serious and fatal ADR among hospitalized patients is
6.7% and 0.32%, respectively.3 Sometimes, ADR-related costs,
such as hospitalization, surgery and lost productivity, exceed
the cost of the medications.4 The recent epidemiological studies
have estimated that adverse drug reactions are the fourth to
sixth leading causes of death.5 Moreover, detection of ADRs
has become increasingly signiﬁcant because of introduction of
a large number of potent toxic chemicals as drug in last two
or three decades. Thus, it became very crucial to monitor both
known and unknown adverse effects of medicines.
As per WHO, pharmacovigilance is an activity concerned
with the detection, assessment, understanding, management
and prevention of adverse reactions to medicines, contributes
to their safe and rational use.6 ADR can also be deﬁned as
‘‘an appreciably harmful or unpleasant reaction, resulting
from intervention related to the use of a medicinal product,
which predicts hazard from future administration and war-
rants prevention or speciﬁc treatment, or alteration of the
dosage regimen, or withdrawal of the product.” Though
ADRs are of great concern to the general public, medical pro-
fession, pharmaceutical industry and regulatory authorities,
the concept of ADR reporting is still new in India and report-
ing of ADRs is scarce. Govt. of India under the aegis of Min-
istry of Health & Family Welfare has also initiated
Pharmacovigilance Programme of India and established
adverse drug reaction monitoring centres in various tertiary
care hospitals across the country to monitor ADRs.7 North-
east region comprised of 8 Indian states with varied tribal com-
munity and ethnicity. However, from this region still there is
underreporting of ADRs. Hence, this study was undertaken
to record and analyse adverse drug reactions reported from
various departments of a tertiary care hospital situated at
Guwahati, known as gateway to Northeast India. We have
also analysed ADRs for causality and severity.
2. Methods
An observational, cross-sectional study was carried out for
7 months from January 2015 to July 2015 at outpatient and
inpatient setting of a tertiary care hospital in Guwahati,
Northeast India. Permission from Institutional Ethical Com-
mittee of the hospital was obtained prior to the initiation of
this study. ADRs were reported from outpatient departments
as well as from wards of cardiology, dermatology, gynaecol-
ogy, haematology, medicine, ophthalmology, paediatric, psy-
chiatry, TB and chest, and neurology department of the
hospital. The contact number and email id of study authors
were circulated among the physicians of respective depart-
ments to facilitate reporting of ADR. Those cases which were
identiﬁed and reported by physicians of this hospital were con-
sidered as an ADR and recorded. The collected information
included patient’s initial, age, gender, reporting department
of the hospital, description of the reaction, duration of reac-
tion, name of the suspected drug causing reaction, and out-
comes. Drugs causality assessment was performed by
Naranjo’s probability assessment scale8 and Hartwig’s crite-Please cite this article in press as: Lihite RJ et al. A study on adverse drug reactions in
10.1016/j.ajme.2016.05.007rion9 was used for severity assessment. Rechallenge was not
attempted in any patient. Outcome of the patients with ADR
were recorded as fatal, fully recovered (patient fully recovered
during study period), recovering (patient recovering, but not
fully recovered during study period) and unknown (insufﬁcient
information and not documented).
2.1. Inclusion criteria
All the suspected ADRs that may be due to the medications,
both prescribed and over the counter, taken by patients either
as inpatients or outpatients, that were ultimately noted.
2.2. Exclusion criteria
The use of alternative system of medicines such as Ayurveda,
Homeopathy, Unani, etc. as well as over prescribing, over
dosage, excess consumption and patients taking more than
ten prescription drugs were excluded. All mentally retarded,
drug addicted, and unconscious patients were also excluded
from the study. Patients admitted due to alcohol or drug
abuse, a suicide attempt or admissions planned more than
24 h in advance were not recorded.
Naranjo ADR probability scale for causality assessment.8a tertiary care hospital of Northeast India, Alex J Med (Yes2016),Nohttp://dDo not
know1 Are there previous conclusive reports
on this reaction?+1 0 02 Did adverse event appear after the
suspected drug was administered?+2 1 03 Did the adverse reaction improve when
the drug was discontinued or a speciﬁc
antagonist was administered?+1 0 04 Did the adverse reaction appear when
the drug was readministered?+2 1 05 Are there any alternative causes (other
than the drug) that could on their own
have caused the reaction?1 +2 06 Did the reaction reappear when placebo
was given?1 +1 07 Was the drug detected in the blood (or
other ﬂuids) in concentration known to
be toxic?+1 0 08 Was the reaction more severe when the
dose was increased or less severe when
the dose is decreased?+1 0 09 Did the patient have a similar reaction
to the same drug or similar drugs in any
previous exposure?+1 0 010 Was the adverse event conﬁrmed by any
objective evidence?+1 0 0ADR probability classiﬁcationx.ScoreCausality assessment scoreDeﬁnite 9Probable 5–8Possible 1–4Doubtful 0doi.org/
Table 1 Age and gender wise distribution of patients with
ADRs.
Age range Male Female Total patients (%)
61–10 7 4 11(5.0)
11–20 19 15 34(15.5)
21–30 31 51 82(37.4)
31–40 18 27 45(20.5)
41–50 13 17 30(13.6)
51–60 9 3 12(5.4)
P61 4 1 5(2.2)
Total patients 101 118 219
Table 2 Department wise distribution of patients with ADRs.
SI.
no.
Departments Number of patients with ADR (%),
N= 219
1 Dermatology 138(63.01)
2 Haematology 40(18.26)
3 Psychiatry 26(11.87)
4 Medicine 3(1.36)
5 TB & Chest 3(1.36)
6 Cardiology 2(0.91)
7 Gynaecology 2(0.91)
8 Paediatric 2(0.91)
9 Neurology 2(0.91)
10 Ophthalmology 1(0.45)
A study on ADRs in Northeast India 3Hartwig severity assessment scale.9As per this scale ADRs were classiﬁed as follows:P
11leas
0.10Mild reactions which were self limiting and able to resolve over
time without treatment and did not contribute to prolongation
of length of stay.2 Moderate ADRs were deﬁned as those that required therapeutic
intervention and hospitalization prolonged by 1 day but
resolved in <24 h or change in drug therapy or speciﬁc
treatment to prevent a further outcome.3 Severe ADRs were those that were life threatening, producing
disability and those that prolonged hospital stay or led to
hospitalization, required intensive medical care, or led to the
death of the patient.2.3. Statistical analysis
Description statistics were used for data analysis. For non-
normally distributed continuous data, median (interquartile
range) was calculated.
3. Results
In this study, 303 patients were reported to experience ADR
during study period. Eighty-four ADR cases were discarded
from the study because in these cases more than one offending
drug was suspected. Out of 219 patients, 101 (46.1%) patients
were male while 118 (53.8%) patients were female. Of which,
124 patients had single ADR followed by 73 patients who were
with two ADRs, 19 patients who were with three ADRs and 3
patients who were with four ADRs. Most of the patients
(91.7%) were reported from outpatient departments and rests
(8.2%) were reported from inpatient department admitted to
various wards of the hospital. The median age of the patients
was 29 (18). The youngest patient was of 4 months and oldest
of being 76 years. Majority of the patients (37.4%) experienced
ADRs belonged to age group of 21–30 years (Table 1).
According to department wise distribution of patients with
ADRs, majority of the patients with ADR were reported from
dermatology department (63.01%) followed by haematology
department (18.26%), and psychiatry department (11.87%)
(Table 2).
In this study, 255 ADRs were reported from various
departments of the hospital (Table 3). The median duratione cite this article in press as: Lihite RJ et al. A study on adverse drug reactions in
16/j.ajme.2016.05.007of the ADR was 20(29). Out of total ADRs, commonly
reported ADR was acne (18.03%) followed by itching
(7.84%) and melasma (5.1%). The topical steroid (betametha-
sone sodium phosphate) was reported to cause majority of
ADRs (23.13%) followed by topical steroid (clobetasol propi-
onate) (9.41%), imatinib (5.88%), derobin ointment (salicylic
acid) (3.92%) and paracetamol (3.13%) (Table 3). Skin was
the most commonly affected organ system (63.52%) followed
by nervous system (15.29%), digestive system (8.62%), and
cardiovascular system (2.35%) (Table 4).
According to the Naranjo’s algorithm scale, 240(94.1%)
suspected ADRs were possible, 10(3.9%) ADRs were proba-
ble, and 2(0.7%) ADRs were deﬁnite. As per Hartwig severity
assessment scale, majority of the ADRs were mild (222,
87.0%), 32 (12.5%) ADRs were moderate, and 1(0.3%)
ADR report was severe. Most of the patients with ADR
(239, 93.7%) were completely recovered after treatment and
10(3.9%) ADRs were classiﬁed as ‘unknown outcomes’ due
to lack of follow-up and incomplete information (Table 5).
4. Discussion
In our study, 231 suspected offending drugs were reported to
induce various ADRs. Of which majority (92.6%) of the drugs
were withdrawn for the management of ADR and rechallenge
was not performed in any patient. Majority of ADRs were
reported from female patients than from male. Paediatric10
and geriatric11 patients are vulnerable groups, supposed to
experience ADR more often. However, in our study adult
patients belonged to age group of 21–30 years were reported
to experience maximum number of ADRs. It is likely that this
population is attending hospital more frequently and is a
major population receiving drug therapy.
This study was conducted in one of the tertiary care hos-
pitals of Northeast India and there is likely to be variation
between different hospitals because of differences in the local
population characteristics and the specialties within the hos-
pitals. In this hospital, most of the ADRs were reported from
dermatology department. It was observed that the patients
with cutaneous ADRs were referred to dermatology depart-
ment by the physicians of other department, and thus this
may have resulted into high reporting form dermatology
department of this hospital. In general, medicine department
relies on drug therapy to the maximum. However, low report-
ing (1.7%) was observed from medicine department. Froma tertiary care hospital of Northeast India, Alex J Med (2016), http://dx.doi.org/
Table 3 Suspected drugs and their reported ADRs.
Sl.
no.
Suspected drugs Number of
ADRs,
N= 255
ADRs (frequency of occurrence)
1 Betamethasone sodium phosphate (topical) 58 Acne(23), Itching(3), Erythematous Skin rash(2), Aggravated
tinea, Melasma(10), Hypertrichosis(3), Telangiectasis(4), Freckles,
Rosacea, Skin Atrophy(2), Hyperpigmentation, Acneiform
lesions, Skin erosion, Skin Striae(2), Dandruﬀ, Truncal Acne,
Acneform eruption
2 Clobetasol propionate (topical) 24 Acne(11), Eczema over hand, Erythema, Dry skin (2), Skin rash
(purpurea), Skin ﬁssures with erythema, Rosacea, Allergic
reaction, Melasma, Aggravated Acne (4)
3 Imatinib 15 Skin discolouration, Blackness of skin (4), Scrotal edema,
Abdominal swelling, Erythematous skin rash (2), Diarrhoea, Pain
in leg, Bone marrow suppression, Itching over head, Mucositis,
Headache
4 Derobin ointment (Salicylic acid-1.15%, Dithranol-
1.15%, Coal tar-5.3%)
10 Dermatitis, Itching, Irritant Contact dermatitis (7), Tinea
Incognito
5 Paracetamol 8 Fixed drug eruption(5), Erythema, Itching over hands & palms,
Skin rashes
6 Bortezomib 7 Pneumonia with respiratory distress, Vision problem, Knee pain,
Burning sensation in chest, Constipation, Tastelessness, Oral
ulcers
7 Cytarabine 6 Pancytopenia, Hypersensitivity, Mucositis, Neutropenia, Knee
pain, Reddening of legs
8 Mometasone furoate 6 Dermatitis, Itching(2), Erythema, Papular eruption,
Photosensitivity
9 Ceﬁxime trihydrate 6 Toxic Epidermal Necrolysis (TEN), Burning sensation,
Hyperpigmentation, Skin rash, Urticaria, Fever
10 Phenytoin sodium 6 Lichenoid Drug Eruption, Erythema, Papular lesions,
Maculopapular Skin rash, Exfoliative dermatitis, Gum
hypertrophy
11 Clobetasol butyrate (topical) 6 Acne (5), Facial dermatitis
12 Methotrexate 5 Diarrhoea, Hair loss, Weight loss, Bullous Skin rashes, Mucositis
13 Prednisolone acetate 5 Acne (3), Comedones, Rosacea
14 Ketoconazole 4 Erythema, Papular lesions, Itching, Burning sensation
15 Triderm ointment (Gentamycin sulphate-0.5 mg,
Betamethasone dipropionate-0.64 mg, Clotrimazole-
10 mg) (topical)
4 Atrophy, Erythematous skin rashes(2), Hyperpigmentation
16 Fluconazole 4 Erythematous skin rashes (2), swelling on scrotal skin, Skin rash
17 Diprovate-N ointment (Betamethasone 0.05%
+Neomycin sul. 0.5%)
4 Erythematous maculopapular lesions(2), Itching(2)
18 Olanzapine 4 Extrapyramidal Symptoms (2), excessive sedation, Urinary
retention
19 Clonazepam 3 Palpitation, Decreased sleep, Dryness of mouth
20 Diclofenac gel 3 Irritant Contact dermatitis (2), herpes zoster
21 Betamethasone dipropionate (topical) 3 Acne (2), Freckles
22 Risperidone 3 Extrapyramidal symptoms (2), Vomiting
23 6 Mercaptopurine 3 Diarrhoea, Erythrocytopenia, Jaundice
24 Iron-Sucrose Inj. (Saccharated iron oxide) 3 Rigor, Vomiting, Pain at infusion site
25 Cycloserine 3 Restlessness, Suicidal tendency, Vomiting
26 Haloperidol 3 Akathisia, Extrapyramidal Symptoms (2)
27 Naltrexone 2 Decreased appetite, Episodic Irritability
28 Dexamethasone 2 Abnormal hair growth on face, Adrenal suppression
29 Herbal Medication (topical) 2 Skin Rash, Aggravated Plaque over scalp
30 Hydrocortisone 2 Melasma, Acne
31 Clobetamil-G ointment (Clobetasol propionate-
0.05%, Gentamycin sulphate-0.1%)
2 Melasma, Hyperpigmentation
32 Aculip-H 2 Disturbed sleep, Crawling sensation
33 Temovate ointment (Clobetasol Propionate) 2 Papular Rash, Erythema
34 Homeopathic & Ayurvedic Medicine (topical) 2 Skin Rash, Itching
35 Valproin Syrup (Valproate sodium) 2 Steven Johnson’s Syndrome, Skin rash
36 Doxycycline 2 Itching, Photosensitive allergic reaction
37 Vaccine DPT (Tetanus/Diphtheria/Pertussis) 2 Fever, Seizures
38 Diclofenac Sodium 2 Fixed Drug eruption, Urticaria
4 R.J. Lihite et al.
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Table 3 (continued)
Sl.
no.
Suspected drugs Number of
ADRs,
N= 255
ADRs (frequency of occurrence)
39 Zincofer (Ascorbic acid/Pyridoxin HCl/Folic Acid/
Ferrous fumarate, etc.)
2 Giddiness, Headache
40 Triglow Cream (hydroquinol with tretinoin
ﬂuocinolone acetonide)
2 Telangiectasis, Acneform rash
41 Blood transfusion 2 Fever, Rigor
42 Mustard Oil (Brassica Nigra seed oil) 2 Oedema, Exfoliative dermatitis
43 Rituximab 1 Respiratory paralysis
44 Lenalidomide 1 Diarrhoea
45 Cyclosporine 1 Kidney dysfunction
46 Candid B ointment (Beclomethasone dipropionate
0.025%+ Clotrimazole 1%)
1 Irritant contact dermatitis
47 Ayurvedic Medication (topical) 1 Itching
48 Olay Complete defence moisturizing lotion (Zinc
oxide/Octinoxate)
1 Itching
49 Cortisone acetate 1 Acneform eruption
50 Karpin lotion (Tartaric acid-2%, Phenol-0.2% in
aq.soln.)
1 Contact dermatitis
51 Betamil-GM ointment (Betamethasone dipro.-0.05%,
Gentamycin sulph. 0.1%, Miconazole nitra.2%)
1 Eczematoid dermatitis
52 L-asparaginase 1 Abdominal pain
53 Minoxidil lotion 1 Dizziness
54 Sodium valproate 1 Mucositis
55 Methyl prednisolone 1 Hyperglycaemia
56 B-tex lotion(salicylic acid-10%, camphor, boric acid) 1 Contact dermatitis
57 Gatiﬂoxacin eye drops 1 Allergic contact dermatitis
58 Clobetasol propionate (topical) 1 Acne
59 Targocid 1 Anaphylactic reaction
Table 4 Organ system affected by ADRs.
Organ system Number of ADRs (%), N= 255
Skin 162(63.52)
Nervous 39(15.29)
Digestive 22(8.62)
Cardiovascular 6(2.35)
Genitourinary 2(0.78)
Respiratory 2(0.78)
Endocrine 1(0.39)
Musculoskeletal 1(0.39)
Other 20(7.84)
Table 5 Causality and severity assessment of ADRs and their
outcomes.
Parameters Number of ADRs (%), N= 255
Causality
Doubtful; 60 3(1.1)
Possible; 1–4 240(94.1)
Probable; 5–8 10(3.9)
Deﬁnite; P9 2(0.7)
Severity
Mild 222(87.0)
Moderate 32(12.5)
Severe 1(0.3)
Outcomes
Recovered 239(93.7)
Continuing 5(1.9)
Recovering 0(0)
Unknown 10(3.9)
Fatal 1(0.3)
A study on ADRs in Northeast India 5previous studies, commonly reported cutaneous ADRs were
urticaria, ﬁxed drug eruptions, acneform eruptions, macu-
lopapular rashes, and Steven Johnson syndrome (SJS).12,13
In this study, acne, itching, melasma, contact dermatitis,
rashes, and erythematous rashes were commonly reported
ADRs among cutaneous reactions. As reported, SJS and
toxic epidermal necrolysis (TEN) are rare but potentially life
threatening serious ADRs.14 In our study, one report of each
SJS and TEN was reported due to valproate sodium and
ceﬁxime trihydrate respectively. As reported, skin is the most
commonly affected organ system.15 In agreement with this, in
our study most of the patients have experienced skin
disorder.
In this study, majority of the ADRs were associated
with topical application of drug. Topical steroid ointmentPlease cite this article in press as: Lihite RJ et al. A study on adverse drug reactions in
10.1016/j.ajme.2016.05.007containing betamethasone propionate, and clobetasol were
commonly reported to induce acne, itching, erythematous
rash, aggravated tinea, melasma, hypertrichosis, telangiectasis,
freckles, rosacea, skin atrophy, hyperpigmentation, acneiform
lesions, erosion, striae, dandruff, truncal acne, acneform
eruption, and dry skin. Paracetamol is also reported as one
of the offending drugs to induce ﬁxed drug eruption, erythema,a tertiary care hospital of Northeast India, Alex J Med (2016), http://dx.doi.org/
6 R.J. Lihite et al.itching over hands and palms, and rashes. The ADR reports of
lichenoid drug eruption, erythema, papular lesions, macu-
lopapular skin rash, exfoliative dermatitis, and gum hypertro-
phy were reported due to phenytoin sodium. Beside these,
cytarabine induced pancytopenia, hypersensitivity, mucositis,
neutropenia, knee pain, and reddening of legs were commonly
reported from haematology department of this hospital.
According to Naranjo’s scale, from south Indian stud-
ies16,17 most of the reported ADRs were probable, where in
this study most of the ADRs (93.7%) were classiﬁed as possi-
ble, and only 10 ADR reports were probable. As per Hartwig
criteria most of the ADR reports were mild in nature and
recovered during study period. Very few ADRs (1.9%) were
not recovered.
In this hospital, it was observed that the documentation of
ADRs were unintentionally get missed which could be because
of work related stress and forgetfulness, lack of knowledge and
awareness about the importance of drug safety monitoring,
poor knowledge of ADR reporting programme objectives,
and busy outpatient setting, and many clinicians do not con-
sider reporting a priority. This study suffers the main draw-
back of spontaneous reporting system i.e. underreporting.
Thus, ADR monitoring should be strengthened in this diversi-
ﬁed region by sensitizing and encouraging healthcare providers
to report ADRs.
5. Conclusion
The topical steroid (betamethasone sodium phosphate) was
reported to cause majority of ADRs. The commonly reported
ADR in this study was acne. This study suggests that there is a
need of spontaneous ADR reporting from all the departments
of this tertiary care hospital for monitoring and assessment of
ADRs. This study also warrants further research in this part of
India for the development of possible intervention strategies to
reduce burden of ADRs.
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